Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 43

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 43
---
furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of distribution of such tender
offer materials or at the time of a general meeting held to consider our initial business combination, as applicable, as it will be up
to the directors of the post-combination business to determine executive officer and director compensation.

We have entered into a registration rights agreement
with respect to the founder shares, Private Placement Units (and underlying securities) and units (and underlying securities) issued upon conversion
of working capital loans (if any), which is described under Item 12.

On January 29, 2025, we issued a new unsecured
subscription promissory note to the sponsor (the “Subscription Promissory Note”) in connection with the amended and restated
units purchase agreement, pursuant to which we may borrow up to an aggregate principal amount of $1,100,000 working capital loans. The
sponsor further agrees that such loans shall be converted into Private Placement Units, at the price of $10.00 per unit. To the extent
the amount of such loans is less than $1,100,000, the sponsor acknowledges and agrees that it (or, if applicable, it and any transferees
of Private Placement Units) shall surrender for cancellation any and all rights to up to an aggregate of 110,000 Private Placement Units
at $10.00 per unit.

Related Party Policy

We have adopted a Code of Conduct requiring us
to avoid, wherever possible, all conflicts of interests, except under guidelines or resolutions approved by our board of directors (or
the appropriate committee of our board of directors) or as disclosed in our public filings with the SEC. Under our Code of Conduct, conflict
of interest situations will include any financial transaction, arrangement or relationship (including any indebtedness or guarantee of
indebtedness) involving the company.

In addition, our audit committee, pursuant to
a written charter, will be responsible for reviewing and approving related party transactions to the extent that we enter into such transactions.
An affirmative vote of a majority of the members of the audit committee present at a meeting at which a quorum is present will be required
in order to approve a related party transaction. A majority of the members of the entire audit committee will constitute a quorum. Without
a meeting, the unanimous written consent of all of the members of the audit committee will be required to approve a related party transaction.
Our audit committee will review and approve all